Skip to main content
OpenTrials

Clinical trial condition

Hypogammaglobulinemia

Explore clinical trials studying Hypogammaglobulinemia. Study availability and eligibility vary by location and protocol.

17 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Hypogammaglobulinemia trial results

Recruiting

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

NCT05645107

Conditions
Agammaglobulinemia, B-cell Chronic Lymphocytic Leukemia, Bacterial Infections, +25 more
Locations
  • GC2202 Study Site 115 Huntington Park, California, United States
  • GC2202 Study Site 103 St. Petersburg, Florida, United States
  • GC2202 Study Site 111 Bethesda, Maryland, United States
  • GC2202 Study Site 109 Greenville, North Carolina, United States
View all 62 locations
View Trial Details
Recruiting

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

NCT06976476

Conditions
Agammaglobulinemia, Blood Protein Disorders, Cardiovascular Diseases, +18 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity) Commack, New York, United States
View Trial Details
Recruiting

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

NCT05678621

Conditions
Agammaglobulinemia, Blood Protein Disorders, Haematological Malignancy, +16 more
Locations
  • Canberra Hospital Garran, Australian Capital Territory, Australia
  • Concord Hospital Concord, New South Wales, Australia
  • Royal North Shore St Leonards, New South Wales, Australia
  • Monash Medical Centre Clayton, Victoria, Australia
View Trial Details
Completed

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

NCT04502030

Conditions
Agammaglobulinemia, Blood Protein Disorders, Chronic Disease, +18 more
Locations
  • Octapharma Research Site St. Petersburg, Florida, United States
  • Octapharma Research Site Columbus, Georgia, United States
  • Octapharma Research Site Macon, Georgia, United States
  • Octapharma Research Site New Orleans, Louisiana, United States
View all 84 locations
View Trial Details
Completed

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

NCT00161993

Conditions
Agammaglobulinemia, Blood Protein Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +10 more
Locations
  • Tampere University Hospital Tampere, Finland
  • Turku University Central Hospital Turku, Finland
  • SU/Sahlgrenska Gothenburg, Sweden
  • University Hospital Lund Lund, Sweden
View Trial Details
Completed

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

NCT01581593

Conditions
Agammaglobulinemia, Antibody Deficiency, Blood Protein Disorders, +11 more
Locations
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Allergy Associates of the Palm Beaches North Palm Beach, Florida, United States
  • Family Allergy & Asthma Center, PC Atlanta, Georgia, United States
  • Rush University Chicago, Illinois, United States
View all 15 locations
View Trial Details

Related conditions